Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C  

作　　者：Kaori Mochizuki Tatehiro Kagawa Shinji Takashimizu Kazuya Kawazoe Sei-Ichiro Kojima Naruhiko Nagata Atsushi Nakano Yasuhiro Nishizaki Koichi Shiraishi Masaru Itakura Norihito Watanabe Tetsuya Mine Shohei Matsuzaki 

机构地区：[1]Department of Internal Medicine,Division of Gastroenterology,Tokai University School of Medicine,Bohseidai,Isehara 259-1193,Japan

出　　处：《World Journal of Gastroenterology》2004年第5期733-736,共4页世界胃肠病学杂志（英文版）

摘　　要：AIM:To test whether in vitro incubation of peripheral blood mononuclear cells (PBMC) with interferon (IFN) could efficiently decrease hepatitis C virus-RNA (HCV-RNA) amount and to analyze whether this effect was associated with clinical response to IFN.METHODS:Twenty-seven patients with histologically proven chronic hepatitis C were given intravenous administration of 6 million units (MU) IFN-β daily for 6 weeks followed by three times weekly for 20 weeks. PBMC collected before IFN therapy were incubated with IFN-β and HCV-RNA in PMBC was semi-quantitatively determined.RESULTS: Twenty-five patients completed IFN therapy.Eight patients (32%) had sustained loss of serum HCV-RNA with normal serum ALT levels after IFN therapy (complete responders).HCV-RNA in PBMC was detected in all patients,whereas it was not detected in PBMC from healthy subjects.In vitro administration of IFN-β decreased the amount of HCV-RNA in PMBC in 18 patients (72%). Eight of these patients obtained complete response. On the other hand,none of the patients whose HCV-RNA in PBMC did not decrease by IFN-β was complete responders. Multiple logistic regression analysis revealed that the decrease of HCV-RNA amount in PBMC by IFN-β was the only independent predictor for complete response (P<0.05).CONCLUSION:The effect of in vitro IFN-β on HCV in PBMC reflects clinical response and would be taken into account as a predictive marker of IFN therapy for chronic hepatitis C.AIM:To test whether in vitro incubation of peripheral blood mononuclear cells (PBMC) with interferon (IFN) could efficiently decrease hepatitis C virus-RNA (HCV-RNA) amount and to analyze whether this effect was associated with clinical response to IFN. METHODS:Twenty-seven patients with histologically proven chronic hepatitis C were given intravenous administration of 6 million units (MU) IFN-β daily for 6 weeks followed by three times weekly for 20 weeks.PBMC collected before IFN therapy were incubated with IFN-β and HCV-RNA in PMBC was semi-quantitatively determined. RESULTS:Twenty-five patients completed IFN therapy. Eight patients (32%) had sustained loss of serum HCV-RNA with normal serum ALT levels after IFN therapy (complete responders).HCV-RNA in PBMC was detected in all patients, whereas it was not detected in PBMC from healthy subjects. In vitro administration of IFN-β decreased the amount of HCV-RNA in PMBC in 18 patients (72%).Eight of these patients obtained complete response.On the other hand, none of the patients whose HCV-RNA in PBMC did not decrease by IFN-β was complete responders.Multiple logistic regression analysis revealed that the decrease of HCV-RNA amount in PBMC by IFN-β was the only independent predictor for complete response (P<0.05). CONCLUSION:The effect of in vitro IFN-β on HCV in PBMC reflects clinical response and would be taken into account as a predictive marker of IFN therapy for chronic hepatitis C.

关 键 词：Adult Antiviral Agents dosage Drug Resistance  Viral Female HEPACIVIRUS Hepatitis C  Chronic Humans In Vitro INTERFERON-BETA Leukocytes  Mononuclear Male Middle Aged Predictive Value of Tests RNA  Viral 

分 类 号：R512.63[医药卫生—内科学] R979.5[医药卫生—临床医学]